Comment from Amy Brunt
AnonymousSupportAcademic
Summary: Dr. Amy Brunt, a neonatologist, urges the FDA to prioritize and fund CURE ID's work on drug repurposing. She argues that the agency should provide resources to this existing initiative to combat infectious diseases in vulnerable populations without duplicating efforts.
My name is Dr. Amy Brunt, and I'm a neonatologist writing to urge the FDA to prioritize CURE ID’s work on repurposing drugs and to provide the resources and support necessary for its success. There is no need to duplicate work when CURE ID is already in place. It's vitally important that we find ways of combatting infectious disease, particularly for our vulnerable populations, like babies, and I urge the FDA to provide appropriate funding and resources for CURE ID.